Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies

OBJECTIVE: Depressive symptoms are common in schizophrenia and can worsen outcomes and increase suicide risk. Lurasidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar I disorder. This post ho...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:CNS Spectr
Asıl Yazarlar: Nasrallah, Henry A., Cucchiaro, Josephine B., Mao, Yongcai, Pikalov, Andrei A., Loebel, Antony D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Cambridge University Press 2014
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4411643/
https://ncbi.nlm.nih.gov/pubmed/24955752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1017/S1092852914000285
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller